|Application ||WB, IHC, IF, FC, IP, E|
|Other Names||Prostate-specific antigen, PSA, Gamma-seminoprotein, Seminin, Kallikrein-3, P-30 antigen, Semenogelase, KLK3, APS|
|Target/Specificity||PSA from human sperm plasma|
|Application Note||ELISA : For coating, order Ab without BSA|
Flow Cytometry : 0.5-1ug/million cells
Immunofluorescence : 0.5-1.0 µg/ml
Western Blotting : 0.5-1.0 µg/ml
Immunoprecipitation : 0.5-1 µg/500ug protein lysate
Immunohistology (Frozen & Formalin-fixed) : 0.5-1.0 µg/ml for 30 minutes at RT
(Staining of formalin-fixed tissues requires boiling tissue sections in 1mM EDTA Buffer, pH 7.5-8.5, for 10-20 min followed by cooling at RT for 20 minutes).
|Format||0.5 ml at 200ug/ml with BSA and azide|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Prostate Specific Antigen (PSA) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Recognizes a single protein of 33-34kDa, identified as the prostate specific antigen (PSA). This MAb is highly specific to PSA and stains prostatic secretory and ductal epithelium in both normal and neoplastic tissues. PSA is a chymotrypsin-like serine protease (kallikrein family) exclusively produced by the prostate epithelium, and abundant in seminal fluid. PSA can be detected in the sera of patients with prostatic carcinoma. It is predominantly complexed to a liver-derived serine protease inhibitor, alpha-1-antichymotrypsin (ACT). A higher proportion of serum PSA is complexed to ACT in prostate cancer than in benign prostate hyperplasia.
1. ISOBM TD-3 Workshop, Tum. Biol. 20 (S1), pp 1-94, Eds. Rye P.D. et al. (1999).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.